Medivation Inc. said a preclinical test of its drug MDV3100 -- aimed at prostate cancer -- showed it also blocked the growth of breast cancer cells.
San Francisco-based Medivation (NASDAQ: MDVN) tested the drug with partner Astellas Pharma Inc. at the University of Colorado in Denver.
No comments:
Post a Comment